Skip to main content

Indaptus Therapeutics, Inc.

INDP
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001857044

No open-market purchases or sales by Indaptus Therapeutics, Inc. insiders were filed in the last 90 days; 9 institutions reported holding it in 13F filings for Q2 2026, worth $1.15M in total; no superinvestor holds it.

Q3 2021 vs. Q2 2021

How the institutions holding Indaptus Therapeutics, Inc. changed between Q2 2021 and Q3 2021.

All holders in Q3 2021All holders in Q2 2021

13F holders of INDP: Q2 2021 compared with Q3 2021
MeasureQ2 2021Q3 2021Change
Holders015+15
Shares0541.7K+541.7K
Value$0$4.24M+$4.24M

New holders (15)

Institutions that held Indaptus Therapeutics, Inc. at the end of Q3 2021 but not at the end of Q2 2021.

Institutions new to INDP in Q3 2021
InstitutionSharesValue% of portfolio
Armistice Capital, LLC381,892$2.99M0.07%
Vanguard Group Inc75,841$594.0K0.00%
Geode Capital Management, LLC27,450$214.0K0.00%
Investment House LLC25,653$201.0K0.01%
Citadel Advisors LLC14,224$111.0K0.00%
Marshall Wace, LLP12,780$100.0K0.00%
Harel Insurance Investments & Financial Services Ltd.2,958$25.0K0.00%
Morgan Stanley556$4.00K0.00%
UBS Group AG132$1.00K0.00%
Wells Fargo & Company64$00.00%
Group One Trading, L.P.13$00.00%
Reilly Financial Advisors, LLC63$00.00%
Cutler Group LP32$00.00%
Advisor Group Holdings, Inc.63$00.00%
Steward Partners Investment Advisory, LLC28$00.00%

Sold out (0)

Institutions that held Indaptus Therapeutics, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.

None.